5-fluorouracil induced cardiotoxicity: Review of the literature

Michael F. Sorrentino, Jiwon Kim, Andrew E. Foderaro, Alexander G. Truesdell


5-fluorouracil (5-FU) is a key chemotherapeutic agent in the treatment of many gastrointestinal
tract adenocarcinomas. Despite its proven therapeutic efficacy, 5-FU also possesses several
undesired cardiac toxicities, including coronary vasospasm, coronary thrombosis, cardiomyopathy,
and sudden cardiac death. This review addresses the incidence, mechanisms of action,
clinical presentation, risk stratification, and management of 5-FU associated cardiotoxicity; it
also highlights the importance of careful pre-administration cardiac risk stratification and
close monitoring during and after drug administration. (Cardiol J 2012; 19, 5: 453-458)


5-fluorouracil; acute coronary syndrome; cardiotoxicity

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl